Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrukinzumab (IMA-638) Allergen Challenge in Mild Allergic Asthma
NCT00410280Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2007
- Primary completion
- May 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anrukinzumab in allergic asthma, sponsored by Pfizer. Started Mar 2007; status: completed.
02
Drugs
anrukinzumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00410280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00410280.